NCT06504719View on ClinicalTrials.gov

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

CompletedOBSERVATIONAL
Enrollment

312

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

September 1, 2024

Conditions
Breast CancerMetastatic Cancer
Interventions
DRUG

Antibody-Drug Conjugates

Patients with advanced breast cancer treated with ADCs

Trial Locations (1)

11524

Hellenic Cooperative Oncology Group, Athens

All Listed Sponsors
lead

Hellenic Cooperative Oncology Group

OTHER